A randomized fMRI study of 38 schizophrenia patients found that clozapine reduced both subjective cannabis craving and amygdala activation to cannabis images significantly more than risperidone after 4 weeks of treatment.
Psychiatrists treating dual-diagnosis schizophrenia/cannabis use disorder; researchers studying antipsychotic effects on addiction; clinical guideline developers.
Clozapine reduced amygdala cannabis cue reactivity significantly more than risperidone (p=0.006)
What the researchers found
Thirty-eight patients with schizophrenia (30 with cannabis use disorder, 8 without) and 20 healthy controls were included. Patients were randomized to clozapine or risperidone.
At baseline, patients with comorbid cannabis use disorder showed higher subjective craving and greater brain activation to cannabis-related images compared to those without CUD and healthy controls, across most regions of interest.
After 4 weeks of treatment, clozapine-treated patients reported significantly greater reduction in craving (F=6.0, p=0.04) and showed a larger decrease in amygdala activation during cannabis-related images compared to risperidone-treated patients (T=3.94, p=0.006).
Subjective craving correlated significantly with thalamus and insula activation during cannabis cue exposure.
The findings provide neurobiological evidence for clozapine's superiority in this dual-diagnosis population, likely through differential effects on dopamine signaling.
Why it matters
Cannabis use disorder in schizophrenia is extremely common and worsens outcomes. Clozapine is often recommended for this population but evidence for why has been limited. This study provides both subjective and neurobiological evidence that clozapine reduces cannabis craving more effectively than risperidone.
The numbers in context
38 patients, 20 controls. Craving reduction: clozapine > risperidone (F=6.0, p=0.04). Amygdala activation decrease: clozapine > risperidone (T=3.94, pFWE=0.006). Craving correlated with thalamus and insula activation.
How the study worked
Randomized fMRI study. 38 schizophrenia patients (30 with CUD, 8 without) and 20 healthy controls. Randomized to clozapine or risperidone. Brain response to cannabis-related, positive, and neutral images at baseline and 4 weeks. ROIs: amygdala, ventral striatum, insula, thalamus, orbitofrontal cortex, anterior cingulate.
What this study cannot tell us
Small sample size (38 patients). Short treatment duration (4 weeks). Unequal group sizes for CUD status. Open-label medication assignment. Cannot determine whether craving reduction translates to actual cannabis use reduction long-term.
How to read the evidence
Moderate. Randomized design with neuroimaging outcomes, but small sample and short duration limit conclusions.
When this study was published
Published in 2018. Clozapine remains a recommended option for schizophrenia with comorbid substance use disorders.
The bigger picture
Dual-diagnosis patients (schizophrenia plus cannabis use disorder) represent one of the most challenging clinical populations. Evidence-based guidance on antipsychotic choice for this group is limited, making this small RCT an important contribution.
Questions still open
- Does clozapine's craving reduction translate to sustained cannabis abstinence? Is the amygdala the key brain region mediating clozapine's advantage? Would other atypical antipsychotics show similar effects?
Common questions
What is cue reactivity?
Why is clozapine not used more often?
Read the original research
Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.
Schizophrenia research, 194, 32-38
Citation
Machielsen, Marise W J; Veltman, Dick J; van den Brink, Wim; de Haan, Lieuwe. (2018). Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.. Schizophrenia research, 194, 32-38. https://doi.org/10.1016/j.schres.2017.03.030
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)